Long-term Outcomes from Proton Therapy for Sinonasal Cancers

Roi Dagan, MD, MS; Haruka Uezono, MD; Curtis Bryant, MD; Adam L. Holtzman, MD; Christopher G. Morris, MS; William M. Mendenhall, MD

From the Department of Radiation Oncology, University of Florida College of Medicine, Jacksonville, FL, USA

Abstract

Purpose: To report long-term disease control, survival, and toxicity after proton therapy for sinonasal cancer.

Patients and Methods: We reviewed 143 cases of adults with nonmetastatic sinonasal cancers treated with primary (18%; n = 26) or adjuvant (82%; n = 117) proton therapy. The most common histologies were squamous cell carcinoma (29%; n = 42), olfactory neuroblastoma (23%; n = 33), and adenoid cystic carcinoma (16%; n = 23). Patients had predominantly advanced-stage disease (T3, 24%, n = 35; T4, 66%, n = 94) and high-grade histology (52%; n = 74). Surgery included endoscopic resection alone (50%) with craniotomy (10%) or open resection (40%), and 31% had gross disease present at radiotherapy. Most (91%) received high-dose (median, 73.6 Gy radiobiological equivalent [GyRBE]; 84% >70 GyRBE) passive-scatter proton therapy using accelerated hyperfractionation (1.2 GyRBE twice daily) and concurrent chemotherapy (70%). Univariate and multivariate models assessed prognostic factors. Grade 3+ toxicities were recorded per Common Terminology Criteria, version 4. Median follow-up was 3.4 years (range, 0.1–12.5 years) overall and 4.9 years (range, 0.9–12.5 years) for living patients.

Results: The 5-year outcomes were as follows: local control (LC), 80%; neck control, 96%; local-regional control, 78%; freedom from distant metastases, 71%; and disease-free survival, 62%; cause-specific survival, 64%; and overall survival, 59%. Surgery improved LC, but only with gross total resection (5-year LC 87% versus subtotal resection 62.9%, and biopsy alone 55% (P, 0.001). Gross residual disease was the only significant prognostic factor for local-regional control on multivariate analysis. High-grade, T4, and local recurrence were associated with decreased overall survival. Late (G3+) toxicity occurred in 22% (32 of 143), including central nervous system necrosis and vision loss in 6% (9 of 143) and 3.5% (5 of 143), respectively.

Conclusion: Proton therapy after gross-total resection provides excellent long-term LC in patients with locally advanced, high-grade sinonasal cancer. Moreover, LC remains strongly associated with long-term survival. With gross disease, about 60% of patients had long-term LC with proton therapy and induction or concurrent chemotherapy.

Keywords: proton therapy; particle therapy; head and neck; outcomes; sinonasal tumors

Introduction

Sinosal cancers are some of the rarest and most diverse head and neck malignancies with an annual incidence in the United States of approximately 1 in 180,000 distributed among dozens of histologic subtypes [1–4]. Patients typically present with advanced disease and undergo aggressive multimodality treatment, including surgery, radiotherapy,
and chemotherapy, despite the lack of prospective clinical trial data to guide therapy [3, 4]. The proximity of these tumor to (or invasion of) vital structures, including the orbits, skull base, cranial nerves, central nervous system (CNS), and visual pathways, presents a formidable challenge to aggressive local therapy. In most studies, local recurrence is the major mode of treatment failure with rates between 30% and 50%, despite surgery and adjuvant 3-dimensional conformal or intensity-modulated photon radiotherapy (IMRT) [1, 5–7], and results with primary radiotherapy are generally more disappointing [8, 9]. With few patients undergoing successful salvage therapy, local recurrence is the leading cause of death among this patient population.

Charged particle therapy, including proton radiation, has increased in popularity for management of this disease site because of its dosimetric advantages [10, 11] with encouraging early outcomes from single- and multi-institutional cohorts [4, 12–14]. A recent meta-analysis and systematic review suggested disease control and survival benefits with proton therapy compared with IMRT [15]. However, limited data are available to assess long-term outcomes. Therefore, we undertook this study to update our initial experience with proton therapy for sinonasal cancers [4], and here, we report long-term disease control, survival rates, major toxicities, and prognostic factors among nearly double the patients, with double the follow-up, of our previous analysis [4].

**Materials and Methods**

Under an institutional review board–approved study, we reviewed the medical records of patients with sinonasal cancers treated with curative-intent primary or postoperative proton radiotherapy at our institution between 2007 and 2018. We excluded patients treated with palliative intent, pediatric patients (younger than 18 years), and those with noncarcinoma histology (mucosal melanoma, bone/soft-tissue sarcoma, and lymphoma), distant metastases, history of prior head and neck cancer or active second malignancy (other than nonmelanoma skin cancers), and any patient with fewer than 6 months of potential follow-up after completion of radiotherapy. In total, 143 patients were eligible for analysis. Staging at the primary site included endoscopy and imaging (computed tomography [CT] and/or magnetic resonance imaging [MRI]). Regional lymph node metastases were staged using neck CT or fluorodeoxyglucose–positron emission tomography/CT (PET/CT), and distant metastases using chest x-ray, chest CT, and/or fluorodeoxyglucose PET/CT.

We previously described our proton therapy technique [4], which is summarized as follows: patients underwent CT simulation in an immobilized supine position on a base-of-skull frame with a 5-point thermoplastic mask, custom neck or occiput support, and shoulder restraints. We used custom oral obturators or stents and dental impressions whenever tolerable for additional immobilization and healthy tissue displacement. We acquired axial images at 1-mm intervals from the vertex to carina with and without intravenous (IV) contrast. We registered preoperative and postoperative imaging (CT and/or MRI) when applicable. We generated a gross tumor volume (GTV) or preoperative GTV based on imaging and operative, endoscopic, or pathologic findings. The standard-risk clinical target volume (CTV1) included the entire operative bed and sinonasal region at risk for subclinical disease and the adjacent skull base. When applicable, we included cranial nerve tracts, orbital and intracranial volumes, and any elective nodal regions in the upper neck in CTV1. The GTV and preoperative GTV to CTV1 expansion was thus anisotropic and varied widely on any given axial slice. We contoured a boost volume, CTV2 (CTV high-risk), as a customized 0- to 5-mm expansion of the GTV or preoperative GTV, which we confined to CTV1. Planning target volume (PTV) margins were 3 mm. The PTV margins were used in aperture design and target coverage evaluation. We contoured the following organs at risk (OARs): globes, optic nerves, chiasm, spinal cord, lenses, lacrimal glands, brainstem, salivary glands, oral cavity, larynx, pharyngeal constrictors, brain, temporal lobes, hippocampi, hypothalamus, pituitary, and brain as healthy tissues at risk.

The proton therapy technique evolved over the study period, marked by a transition from passive-scattered 3-dimensional conformal proton therapy to pencil-beam scanning intensity-modulated proton therapy (IMPT-PBS); however, most patients (127, 89%) received double-scattered proton therapy. Beam arrangements and aperture margins were customized. We used 3 to 4 nonopposed, noncoplanar fields with range modulation to ensure that the spread-out Bragg peak (90% of the mid-spread-out Bragg peak dose) covered the entire radiographic depth of the target. We combined matched fields to improve conformity around complex target volumes with adjacent OARs. We applied distal and proximal margins to the CTV to account for range uncertainty, as previously described [16]. To minimize uncertainties in the treatment planning process, including dose heterogeneity and relative biological effectiveness, we used the minimum allowable field junctions and fields with distal Bragg peaks ending on high-priority OARs, such as the spinal cord, brainstem, or visual pathways [17]. Custom compensators and apertures further maximized dose conformity and reduced the effects of tissue heterogeneity. Compensator smoothing or
Proton therapy for sinonasal cancer

Dagan et al (2021), *Int J Particle Ther* 202

smearing mitigated the effect of geometric uncertainties on radiographic depth and proton range. Nine patients (6%) received IMRT for technical or logistical reasons (ie, cyclotron downtime or unavailability) and 7 patients (5%) received IMPT-PBS. For IMPT-PBS, the typical field arrangement included of 3 nonopposed, noncoplanar fields with a single anterior-posterior field, and 2 posterior-lateral-oblique fields. The IMPT-PBS plans were planned with multifield optimization, further optimized with robust optimization with a 3-mm margin, with the goal of covering 99% of the CTV and 95% of the PTV with the prescribed dose. For nearly all plans, at least 1 optic nerve and chiasm were limited to a maximum dose of 55 Gy radiobiological equivalent (GyRBE) to 0.1 mL. Brainstem maximum dose to 0.1 mL was similarly limited, although greater doses were accepted when the high-risk target volume abutted the brainstem. The issue of PTV/OAR overlap in the skull base is a major point of tension in planning aggressive radiotherapy for sinonasal and skull base carcinomas. It is an individualized decision, and we heavily weigh the patient’s goals of care. We also consider prognosis, functional status, general health, and family or caretaker input. We ultimately favor target coverage and accept up to prescription doses to OARs when the high-risk target overlaps or abuts the OAR in a high-risk situation, such as a positive margins or gross residual disease. In many of these cases, we have judged that an increased risk of serious complication, such as unilateral blindness, will allow for a necessary, curative therapeutic dose, and we find that many patient’s prefer up to a 50% risk of a major complication if it means increasing their chance to achieve tumor control or improve survival. We have reduced the PTV 95% dose volume ($D_{95}$) to $<95\%$ in only 15% (22 of 143) of patients. The OAR constraints did not differ between patients treated once daily or twice daily.

Most patients ($n = 130$; 91%) received accelerated hyperfractionated proton therapy ($1.2 \text{ GyRBE per fraction}$) twice daily with a minimum 8-hour interval. The dose to PTV1 was 45 to 50.4 GyRBE, and the PTV2 was typically planned to receive an aggregate dose of 74.4 GyRBE; however, fractions and/or target coverage could be reduced to meet OAR objectives and standard fractionation ($2 \text{ GyRBE/once daily}$) could be used at the discretion of the treating physician. The median aggregate dose to PTV2 was 73.6 GyRBE (range, 54–74.4) over 62 fractions (range, 30–62) and 84% of patients received $>70 \text{ GyRBE}$. Patients with negative margins received slightly lower doses (median, 72.4 GyRBE; 53% received $>70 \text{ GyRBE}$), and patients with indeterminate or positive margins were treated similar to those with gross disease. Patients with negative margins received slightly lower doses (median, 72.4 GyRBE; 53% received $>70 \text{ GyRBE}$), and patients with indeterminate or positive margins were treated similar to those with gross disease.

In total, 121 patients (85%) received regional nodal irradiation, including 105 (73%) for elective coverage of the N0 neck and 16 (11%) as primary or postoperative therapy for a clinically or pathologically positive neck tumor; 22 (15%) were observed with a cN0 or pN0 neck tumor. For most of the study, we treated the neck with our previously described photon technique to 46 to 50 Gy in 23 to 25 Gy daily fractions [4]; however, in the latter part of the study, we included the elective neck target in CTV/PTV1 using IMPT-PBS. In either case, when the neck target included high-risk disease, we boosted the neck volume in CTV/PTV2.

One hundred patients (70%) received chemotherapy; of which, 75% received concurrent low-dose cisplatin ($25–30 \text{ mg/m}^2$) once weekly during radiotherapy with the goal of radiosensitization. The remaining 25% received various forms of multidrug induction or concurrent regimens before either surgery or primary radiotherapy. Toward the end of the study period, nearly all patients with advanced (T3–T4) high-grade neuroendocrine histology (sinonasal undifferentiated carcinoma [SNUC], small cell carcinoma, or Hyams grade 4 olfactory neuroblastoma) received induction chemotherapy with 2 cycles of cisplatin and etoposide or 3 cycles of Taxotere, cisplatin, and fluorouracil before concurrent chemoradiotherapy.

Image guidance consisted of orthogonal kilovoltage x-rays for each fraction with cone-beam CT weekly or daily in more-recent years. During the latter half of the study period, we used midtreatment verification CT (and MRI when indicated) for most patients. Proton therapy plans were adapted whenever target coverage and/or OAR sparing deviated significantly from the initial plan. For primary radiotherapy, boost volumes (CTV2/PTV2) were adapted to account for initial response to therapy (including any induction chemotherapy) based on the findings of the verification simulation.

We prospectively collected disease control data and toxicity endpoints for all patients eligible for on-site follow-up at intervals of $\leq 6$ months for 2 years, then annually thereafter. Follow-up typically included endoscopic evaluation and imaging (MRI or CT) of the primary site with annual imaging surveillance for distant metastases. We performed remote follow-up for all other patients and, whenever possible, we obtained source documents (ie, imaging, pathology, and clinical records) to document disease control and toxicity. We analyzed the following endpoints: local control (LC), neck control, local-regional control (LRC), freedom from distant metastases, disease-free survival (DFS, events coded as any recurrence and censored at the time of death), overall survival (OS), and cause-specific survival (CSS, any death with disease present or related to a treatment complication). A local recurrences was any recurrence within or adjacent to the PTV2, including the involved neural tracts or adjacent dura and skull base. A recurrence was deemed marginal when its epicenter was adjacent to or just beyond...
the high-dose region. Lymph node recurrences in the neck (defining neck control) were designated regional recurrences, and all other recurrences, including leptomeningeal progression or dermal metastases in the head and neck, were considered distant metastases.

We used SAS and JMP software for statistical analysis (SAS Institute, Cary, North Carolina). The Kaplan-Meier product-limit method provided estimates of OS, CSS, LC, NC, LRC and DFS. The log-rank test statistic provided estimates of statistical significance between the strata of selected prognostic factors. Proportional hazards regression was used for multiple regression of selected prognostic factors on each endpoint; a backward selection procedure provided the most parsimonious final models. We assessed serious, late-grade 3+ toxicity using the Common Terminology Criteria for Adverse Events, version 4. We reported the single worst toxicity per patient and all grade 3 to 4 visual or CNS toxicities.

Results

Table 1 shows the baseline characteristics of the 143 study patients. Most were male with advanced (T4, 66%) tumors of the nasal cavity/ethmoid sinus (78%), and the most common histology was squamous cell carcinoma (29%), followed by olfactory neuroblastoma (23%), adenoid cystic carcinoma (16%), and SNUC (11%). A significant proportion of patients had orbital (41%), cranial nerve (28%), and/or intracranial invasion (43%) including 8 patients (6%) with parenchymal brain invasion; 52% had high-grade histologic subtypes. Fifty-five patients (38%) had previously undergone surgery and were being treated for subsequent recurrences.

Table 1 also shows the surgical approaches used and the resection outcomes. After combining patients who underwent biopsy alone, subtotal resection, and recurrence at the primary site after gross total resection (GTR), 45 (31%) had gross disease at the primary site at the start of proton therapy. The median follow-up from the start of radiotherapy was 3.4 years (range, 0.4–7.2 years) for all patients and 4.9 years (range, 0.9–12.5 years) for surviving patients. At the time of analysis, 52 patients (36%) had died, including 37 (26%) from disease at the primary site at the start of proton therapy.

Table 2 shows the results of our univariate and multivariate analyses of prognostic factors. Nonnasal and ethmoid primary sites, nonsquamous histology, biopsy alone, extent of resection (subtotal resection [STR] versus GTR), and presence of gross disease were associated with lower LRC on univariate analysis with (or trending toward) statistical significance. However, only the presence of gross disease was independently associated with decreased LC on multivariate analysis. An increased risk of distant metastases was associated with histology, T stage, and surgical approach. Along with high-grade histology and T4 disease (versus T1–T3), progression at the primary site was the most significant factor associated with a worse OS on multivariate analysis. From this, we infer that local recurrence remains a major source of mortality despite the competing risks from distant metastases, intercurrent disease, and treatment-related toxicity (Figure 2).

Figure 1A shows the Kaplan-Meier curves and estimates for the major survival endpoints. At 3 and 5 years, the OS rates were 73% and 59%, CSS rates were 76% and 64%, and DFS rates were 64% and 62%, respectively.

Figure 1B shows the Kaplan-Meier curves and estimates for the major disease control outcomes. At the time of this analysis, 55 patients (38%) had documented disease progression (Figure 2). The most common pattern of progression was distant metastasis, followed by local recurrence; only 1 patient (1%) had an isolated regional recurrence. The median time to progression for all recurrences was 11.5 months (range, 1.6–115.9 months) with 93% of events occurring within 5 years. At 3 and 5 years, the LC rate was 80% and LRC was 78%. The median time to local-regional progression was 12.7 months (range, 2.7–115.9 months), with 93% occurring within 5 years. Marginal recurrences occurred in 9 patients (n = 6%), and the remainder of the local-regional recurrences were in field. The 3- and 5-year estimates for freedom from distant metastases were 76% and 71%, respectively. The median time to distant progression was also 12.7 months, with 95% of events occurring within 5 years. Of the 4 cases (3%) of progression after 5 years, 2 occurred in patients with adenoid cystic carcinoma, 1 with neuroendocrine carcinoma not otherwise specified, and 1 with SNUC. Leptomeningeal progression was the single most-common site of distant metastases, accounting for 35% of cases with distant progression without local-regional recurrence.

Figure 2 illustrates the effect of surgery and extent of resection on LC. When compared with biopsy alone, surgery appears to improve LC (at 5 years, 85% versus 55%; P < 0.01); however, further analysis suggests that the benefit of surgery is limited to GTR because there was no apparent difference between STR and biopsy alone (5-year LC, 63% versus 55%; P = not significant [NS]) Ultimately, as noted above, the presence or absence of gross disease at the primary site at the onset of radiotherapy was the most significant prognostic factor for LC.
| Characteristic                  | Patients or other values, No. (%) |
|--------------------------------|-----------------------------------|
| Age, median (range), y         | 60 (18–82)                        |
| **Presentation**               |                                   |
| Primary                        | 88 (62)                           |
| Recurrence                     | 55 (38)                           |
| **Primary site**               |                                   |
| Nasal cavity/ethmoid           | 112 (78)                          |
| Maxillary                      | 27 (19)                           |
| Frontal/sphenoid               | 4 (3)                             |
| **Histology**                  |                                   |
| Squamous cell carcinoma        | 42 (29)                           |
| Minor salivary carcinoma       | 42 (29)                           |
| Adenoid cystic carcinoma       | 23 (16)                           |
| Adenocarcinoma NOS             | 10 (7)                            |
| Mucoepidermoid carcinoma       | 6 (4)                             |
| Other                          | 3 (2)                             |
| Neuroendocrine carcinoma       | 55 (38)                           |
| Olfactory Neuroblastoma        | 33 (23)                           |
| SNUC                           | 16 (11)                           |
| Small cell carcinoma           | 3 (2)                             |
| Neuroendocrine carcinoma NOS   | 3 (2)                             |
| Othera                         | 4 (3)                             |
| **T stage**                    |                                   |
| T1                             | 7 (5)                             |
| T2                             | 7 (5)                             |
| T3                             | 35 (24)                           |
| T4                             | 94 (66)                           |
| **N stage**                    |                                   |
| N0                             | 127 (89)                          |
| N1                             | 6 (4)                             |
| N2                             | 10 (7)                            |
| **Grade**                      |                                   |
| G1                             | 16 (11)                           |
| G2                             | 33 (23)                           |
| G3                             | 74 (52)                           |
| N/A                            | 20 (14)                           |
| **Orbital invasion**           |                                   |
| Present                        | 58 (41)                           |
| Absent                         | 85 (59)                           |
| **Intracranial invasion**      |                                   |
| Presentb                       | 62 (43)                           |
| Absent                         | 81 (57)                           |
| **Cranial nerve invasion**     |                                   |
| Present                        | 40 (28)                           |
| Absent                         | 103 (72)                          |
| **Surgery**                    |                                   |
| Curative resection             | 117 (82)                          |
| Biopsy only                    | 26 (18)                           |
| **Surgical approach, n = 117** |                                   |
| Endoscopic                     | 58 (50)                           |
| Endoscopic-transcranial        | 47 (40)                           |
| Open                           | 12 (10)                           |
As mentioned, our practice has trended away from aggressive resection for patients with advanced high-grade neuroendocrine histologic subtypes. Among the 32 patients (22%) treated for SNUC, small cell carcinoma, or Hyams grades 3 or 4 olfactory neuroblastoma, 10 received primary radiotherapy (after biopsy alone or subtotal resection) with and without induction or concurrent chemotherapy. At the time of analysis, the crude LC rate was 80% and 40% were alive without evidence of disease. Of the remaining 22 patients in this category who underwent GTR, the LC rate was 68% and 54% remain alive without evidence of disease. When we exclude olfactory neuroblastoma from this analysis, 13% of patients treated with primary radiotherapy developed a local recurrence compared with 15% who underwent GTR. Although we could not perform a more in-depth statistical analysis because of limited data, these findings suggest that a primary nonoperative approach is appropriate for advanced (T4) high-grade neuroendocrine sinonasal cancers.

Serious late-treatment toxicity occurred in 22% of patients, including 5 deaths directly or potentially associated with treatment (Table 3). Treatment-associated deaths included 3 patients with osteoradionecrosis of the skull base resulting in meningitis or encephalitis, 1 patient with CNS necrosis, and 1 patient who died from pulmonary embolism secondary to a deep venous thrombosis.

As mentioned, our practice has trended away from aggressive resection for patients with advanced high-grade neuroendocrine histologic subtypes. Among the 32 patients (22%) treated for SNUC, small cell carcinoma, or Hyams grades 3 or 4 olfactory neuroblastoma, 10 received primary radiotherapy (after biopsy alone or subtotal resection) with and without induction or concurrent chemotherapy. At the time of analysis, the crude LC rate was 80% and 40% were alive without evidence of disease. Of the remaining 22 patients in this category who underwent GTR, the LC rate was 68% and 54% remain alive without evidence of disease. When we exclude olfactory neuroblastoma from this analysis, 13% of patients treated with primary radiotherapy developed a local recurrence compared with 15% who underwent GTR. Although we could not perform a more in-depth statistical analysis because of limited data, these findings suggest that a primary nonoperative approach is appropriate for advanced (T4) high-grade neuroendocrine sinonasal cancers.

Serious late-treatment toxicity occurred in 22% of patients, including 5 deaths directly or potentially associated with treatment (Table 3). Treatment-associated deaths included 3 patients with osteoradionecrosis of the skull base resulting in meningitis or encephalitis, 1 patient with CNS necrosis, and 1 patient who died from pulmonary embolism secondary to a deep venous thrombosis.

As mentioned, our practice has trended away from aggressive resection for patients with advanced high-grade neuroendocrine histologic subtypes. Among the 32 patients (22%) treated for SNUC, small cell carcinoma, or Hyams grades 3 or 4 olfactory neuroblastoma, 10 received primary radiotherapy (after biopsy alone or subtotal resection) with and without induction or concurrent chemotherapy. At the time of analysis, the crude LC rate was 80% and 40% were alive without evidence of disease. Of the remaining 22 patients in this category who underwent GTR, the LC rate was 68% and 54% remain alive without evidence of disease. When we exclude olfactory neuroblastoma from this analysis, 13% of patients treated with primary radiotherapy developed a local recurrence compared with 15% who underwent GTR. Although we could not perform a more in-depth statistical analysis because of limited data, these findings suggest that a primary nonoperative approach is appropriate for advanced (T4) high-grade neuroendocrine sinonasal cancers.

Serious late-treatment toxicity occurred in 22% of patients, including 5 deaths directly or potentially associated with treatment (Table 3). Treatment-associated deaths included 3 patients with osteoradionecrosis of the skull base resulting in meningitis or encephalitis, 1 patient with CNS necrosis, and 1 patient who died from pulmonary embolism secondary to a deep venous thrombosis.
vein thrombosis. This patient was nonambulatory because of a fibula free-flap graft-site infection, and she died during adjuvant therapy. The most common grade 3 to 5 events included skull base bone or soft-tissue necrosis with or without associated cerebrospinal fluid leak (11%). Five patients (3.5%) developed unilateral vision loss; all of whom had orbital tumor invasion. We did not include reversible vision loss from cataracts or orbital exenteration as events. Grade 3 to 5 CNS toxicity occurred in 6% of patients. We did not include patients with asymptomatic radiographic changes or minor symptoms that resolved with steroids. Two patients developed treatment-associated tumors, both benign meningiomas. Another patient developed an unknown primary adenocarcinoma metastatic to the liver, which we did not consider to be therapy related. Six patients developed reversible serious grade 3 acute toxicities, including 5 temporary feeding tubes and 1 sepsis.

Discussion

This study reports mature outcomes from, to our knowledge, the largest-published single-institution experience with proton radiotherapy for sinonasal cancers. With a median potential follow-up nearing 5 years, we report encouraging LRC (78%) and OS (59%), despite most patients having locally advanced (T3–T4, 90%) and high-grade (52%) disease. We observed more distant progression (~30%) compared with much of the published literature. However, our findings continue to highlight the importance of aggressive local therapy with a nearly 3-fold benefit in 5-year survival with durable LC, and only 1 in 4 patients alive at 5 years after local recurrence.

Data informing best radiotherapy techniques for management of sinonasal cancers are limited to retrospective research. To date, there is no level 1 evidence, although actively enrolling trials limited by slow accrual are evaluating the role of induction chemotherapy (NCT00707473, NCT03493425). The highest level of evidence addressing radiotherapy techniques derives from a meta-analysis and systematic review of retrospective data, including approximately 1500 patients (~300 treated with charged particle therapy), which demonstrated improved 5-year LRC, DFS, and OS in a subset of patients treated with proton therapy compared with IMRT [15]. The analysis was limited by the vast heterogeneity among the cohorts, sparse data on actuarial disease control, and a disproportionate ratio of high-risk histologic subtype among the photon cohort (50% versus 27%). Lastly, the reported 20% event rate of CNS toxicity with proton therapy, which was significantly worse than that of the photon cohort, remains a concern. Since the publication of that meta-analysis, additional observational studies have documented favorable outcomes with proton therapy [12–14], which are further supported by our mature results. Given the rarity and diversity of this disease group, high-level evidence is unlikely to emerge, and, thus, using the most conformal radiotherapy technique available to deliver aggressive therapy near critical skull base, CNS, and/or ocular structures is justified. Current National Comprehensive Cancer Center guidelines support the use of proton therapy in this disease site [18], and advances in IMPT-PBS delivery, including incorporation of collimation systems [19], may provide additional dosimetric and clinical benefits. That said, the specific dosimetric benefits or effect of dosimetric uncertainties associated with proton therapy vary from case to case.

We acknowledge that our approach differs from that described in the current literature on radiotherapy for sinonasal cancers in more than radiotherapy technique alone. We remained consistent in our approach in large part so we could better evaluate our outcomes. Our rationale for using dose escalation in the postoperative setting (>66 Gy), accelerated hyperfractionation (twice-daily therapy), elective regional nodal radiation, and concurrent systemic therapy are described below.
### Table 2. Results of the univariate (UVA) and multivariate (MVA) analysis.

| Variable                          | Local-regional control | Distant metastasis control | Disease-free survival | Overall survival |
|-----------------------------------|------------------------|----------------------------|-----------------------|------------------|
|                                   | 5-y rate, % UVA P value | 5-y rate, % MVA P value | 5-y rate, % UVA P value | 5-y rate, % MVA P value | 5-y rate, % UVA P value | 5-y rate, % MVA P value |
| Site                              |                        |                            |                        |                  |
| Nasal/ethmoid                     | 83                     | 70                         | 64                    | 65 |
| Other                             | 62                     | 76                         | 56                    | 39 |
| Histology                         |                        |                            |                        |                  |
| Squamous cell carcinoma           | 68                     | 80                         | 65                    | 52 |
| Adenoid cystic carcinoma          | 82                     | 85                         | 77                    | 89 |
| Other minor salivary cancer       | 81                     | 39                         | 38                    | 29 |
| Olfactory neuroblastoma           | 87                     | 78                         | 70                    | 75 |
| Other neuroendocrine cancer       | 77                     | 62                         | 53                    | 45 |
| Grade                             |                        |                            |                        |                  |
| 1                                 | 87                     | 90                         | 87                    | 90 |
| 2                                 | 82                     | 86                         | 76                    | 73 |
| 3                                 | 72                     | 58                         | 48                    | 41 |
| T stage                           |                        |                            |                        |                  |
| T1–%3                             | 84                     | 75                         | 74                    | 65 |
| T4                                | 75                     | 69                         | 56                    | 56 |
| N Stage                           |                        |                            |                        |                  |
| N0                                | 85                     | 68                         | 56                    | 48 |
| N1–N2                             | 78                     | 72                         | 63                    | 61 |
| orbital invasion                  |                        |                            |                        |                  |
| No                                | 79                     | 77                         | 69                    | 62 |
| Yes                               | 79                     | 63                         | 52                    | 56 |
| Intracranial invasion             |                        |                            |                        |                  |
| No                                | 83                     | 74                         | 70                    | 62 |
| Yes                               | 71                     | 68                         | 52                    | 56 |
| Presentation                      |                        |                            |                        |                  |
| Primary                           | 77                     | 69                         | 60                    | 58 |
| Recurrent                         | 100                    | 100                        | 100                   | 78 |
| Surgery                           |                        |                            |                        |                  |
| Biopsy only                       | 55                     | 84                         | 45                    | 49 |
| Curative resection                | 82                     | 70                         | 65                    | 62 |
| Surgery extent                    |                        |                            |                        |                  |
| Gross total resection             | 85                     | 68                         | 66                    | 61 |
| Subtotal resection                | 63                     | 83                         | 63                    | 73 |
| Margin                            |                        |                            |                        |                  |
| Positive/close                    | 82                     | 73                         | 68                    | 62 |
| Indeterminate                     | 83                     | 69                         | 63                    | 64 |
| Negative                          | 87                     | 67                         | 68                    | 53 |
| Surgical approach                 |                        |                            |                        |                  |
| Endoscopic                        | 85                     | 82                         | 76                    | 73 |
| Endo/transcranial                 | 61                     | 44                         | 31                    | 50 |
| Open                              | 83                     | 61                         | 61                    | 52 |
| Gross tumor at radiotherapy       |                        |                            |                        |                  |
| Absent                            | 87                     | 70                         | 68                    | 63 |
| Present                           | 57                     | 80                         | 51                    | 51 |
| Radiotherapy dose                 |                        |                            |                        |                  |
| <70 GyRBE                         | 83                     | 73                         | 68                    | 55 |
| >70 GyRBE                         | 78                     | 71                         | 62                    | 60 |
High-Dose Therapy

Nearly all data on dose-response for postoperative radiotherapy for head and neck cancers are derived from nonsinonasal squamous cell carcinomas treated with photon irradiation; thus, the optimal dose for sinonasal cancers has not been established. Our univariate analysis did not suggest a dose-response above 70 GyRBE; however, we had limited data from patients receiving doses above 70 GyRBE, and this analysis is subject to significant confounders and selection bias. Our bias toward high-dose therapy is driven by the observation that most recurrences occur at the primary site despite gross resection and that local recurrence after primary therapy typically leads to death. Moreover, the surgical approach and outcomes in these cancers differ quite drastically from most other head and neck sites, where en bloc resection with radical margins is not limited by the proximity of the critical skull base, orbital, or CNS anatomy. In our experience, patients who undergo minimally invasive, endoscopic/endonasal, piecemeal resection, commonly have positive, close, or indeterminate surgical margins, reflecting broader trends within the surgical literature [3]. In light of the advanced, infiltrative nature of many of these cancers (90% T3–T4 in our experience), at a minimum, the physician directing adjuvant radiotherapy should suspect a relatively high burden of residual microscopic disease in the surgical bed, and gross residual disease is not a rare occurrence. Therefore, we believe the selection of high-dose therapy is justified in most patients.

Accelerated Hyperfractionation

Although complex, this technique is largely driven by the need for high-dose radiotherapy delivery adjacent to, or overlapping, critical visual-pathway OARs. In nearly all cases of sinonasal cancer, the radiation oncologist is forced to compromise between optimal target coverage and OAR sparing. The available data informing the risk of vision loss from radiation retinopathy and optic neuropathy is suboptimal, but overall suggests that increased dose per fraction (>1.8 Gy/fraction) increases the risk of toxicity, as supported by long-standing principles of radiobiology [20–22]. Although some have suggested an increased relative biological effectiveness with low-dose-per-fraction proton therapy [17], we observed a reassuring 3.5% rate of serious visual pathway toxicity in our cohort despite a significant percentage of patients with orbital invasion and many patients receiving >55 Gy(RBE) to at least one retina and/or optic nerve. This rate of toxicity resembles rates reported with IMRT [6].

![Figure 3. Kaplan-Meier estimates for overall survival with or without local control among the 143 patients included in the analysis.](image-url)
Additional benefits from this dose and fractionation strategy include potentially enhanced LC by counteracting the negative effect of tumor cell repopulation during therapy. This strategy may be particularly pertinent with adjuvant proton therapy after incomplete resection or with primary radiotherapy after partial response to induction chemotherapy. Accelerated radiotherapy may help overcome the effect of treatment delays from transferring care to a proton facility or obtaining insurance approval. At least one study has reported that proton therapy is associated with significant treatment delays for patients with head and neck cancer [23].

**Elective Neck Irradiation**

Controversial in the management of sinonasal cancers, a more detailed discussion of elective neck irradiation is beyond our scope. With rare exceptions, observing the N0 neck is preferred with low-risk histology (adenoid cystic and other low-grade minor salivary gland carcinoma) and early stage squamous cell carcinoma. However, because the risk for occult regional metastases increases with high-grade histology and advanced disease, often crossing the 10% threshold, elective nodal therapy may be justified. Despite the preponderance of such patients in our study, we observed neck recurrences in <5% of patients, suggesting a benefit to elective neck radiotherapy. Others suggest that high salvage rates for regional recurrences may justify observing the regional nodes [24], even when elective lymph node radiotherapy may be effective at reducing the risk of recurrence [24]. However, our preference is to recommend elective radiotherapy because its associated toxicity is less concerning than toxicity from the primary site treatment.

**Concurrent Systemic Therapy**

Our comfort and experience with concurrent low-dose cisplatin with primary or adjuvant photon radiotherapy for head and neck squamous cell carcinoma [25] largely influenced our practice regarding systemic therapy. Chemotherapy was not associated with a benefit in any endpoint in our analysis, a finding almost certainly influenced by confounders and selection bias. Our use of systemic therapy evolved over the study period and varied more than any other treatment factor. Initially,
nearly all patients with a good-performance status received concurrent low-dose cisplatin (25–30 mg/m² once weekly), regardless of risk factors; however, more recently, we have favored adjuvant radiotherapy alone in low-risk patients. Conversely, we have intensified systemic therapy in patients treated with primary radiotherapy for unresectable squamous cell carcinoma or high-risk neuroendocrine tumors. In those cases, we recommend a primary approach of induction chemotherapy, restaging, followed by concurrent chemotherapy and proton therapy for patients without progression. Our data in this scenario are limited but suggest that these patients still achieve favorable LC without oncologic resection, which is supported by recent data on SNUC [26].

Given the heterogeneity of these patients and cancers, individualized management seems appropriate. Our findings do not support a one-size-fits-all approach of maximum safe resection followed by adjuvant therapy. Subtotal resection (debulking surgery) did not improve LC over biopsy alone (5-year LC, 63% versus 55%; P = NS). Therefore, we only recommend aggressive surgery under reasonable expectation of GTR with acceptable morbidity. Among our cohort, we identified a favorable group of patients at low risk for recurrence (~90% LRC), including those with no gross disease at the time of radiotherapy, low-grade histologic subtypes, T1 to T3 disease, and negative margins. Especially considering the potential for serious or irreversible toxicity among long-term survivors, these patients are more likely to receive postoperative doses of 60 to 66 GyRBE using standard fractionation (2 GyRBE/fraction once daily), without concurrent systemic therapy. However, in the absence of such favorable risk factors, we remain committed to our approach until compelling data emerge to inform these decisions. Higher-risk patients may benefit from more-intense therapy, including induction chemotherapy, as discussed above, and we should continue to seek innovative systemic therapy for patients at particularly high risk for distant metastases. Currently, the benefits of recent advances, such as immunotherapy with checkpoint inhibitors, remain unclear. Considering the competing risk of distant metastases, patients with high-grade (nonadenoid cystic) minor salivary gland variants may be considered for less-aggressive adjuvant radiotherapy. Additionally, we recommend thorough staging for systemic progression before radiotherapy, including evaluation of the leptomeninges with spine MRI and/or craniospinal fluid sampling in cases of high-grade neuroendocrine histology and intracranial invasion. We previously described this unique pattern of progression [27], and, given overall poor prognosis, such patients may be better served with systemic therapy alone or palliative care, avoiding the unnecessary toxicity of aggressive head and neck radiotherapy. Lastly, the ever-changing landscape of histologic subtypes in sinonasal cancers can inform or confuse our treatment decisions. In recent years, molecular subtyping has identified newly described entities, such as human papillomavirus-related multiphenotypic sinonasal carcinoma [28], which was likely previously classified as adenoid cystic carcinoma. Additionally, recently described entities include INI (SMARCB1)-deficient sinonasal carcinoma [29] and NUT carcinoma [30]. These cancers differ in prognosis, natural history, and response to therapy from their previous classifications, which further challenges our ability to derive treatment decisions from retrospective data. Given that most of our patients underwent surgery at other institutions, it was not feasible to reassess archived specimens for additional molecular subtyping.

Our study has several limitations. As with all single-institution retrospective studies, the data are subject to selection bias, and the lack of randomized comparisons and a heterogeneous patient population limits our ability to draw meaningful conclusions regarding the benefits and effects of each radiotherapy technique, surgical approach, dose and fractionation regimens, and systemic therapy. Moreover, because many patients could not return to our institution for follow-up because they live significant distances from our center, important disease control or toxicity events may be missing from our records. Additionally, the lack of patient-reported toxicities or quality-of-life outcomes limits our understanding of treatment-associated adverse effects. Lastly, we cannot determine how advances in proton therapy (eg, intensity-modulated proton therapy, adaptive proton therapy, or cone-beam CT-based image-guided proton therapy), diagnostic imaging, and surgical techniques may have influenced our outcomes.

Conclusions

In our cohort of predominantly locally advanced, high-grade sinonasal cancers, proton therapy after gross-total resection provided excellent long-term LC. Even in the presence of gross disease, proton therapy can provide durable LC in nearly 60% of patients. Despite a 30% rate of metastatic progression, LC remains strongly associated with long-term survival. With nearly 1 in 4 patients developing high-grade adverse events, balancing the benefits of LC against significant toxicity remains a challenge. High-grade histologic subtype and T4 disease were associated with increased distant progression, and we recommend a primary nonoperative approach in such patients when a nonmorbid GTR is unlikely.
ADDITIONAL INFORMATION ANDDECLARATIONS

Conflicts of Interest: William M. Mendenhall, MD, is Operating Editor of the International Journal of Particle Therapy. The authors have no other relevant conflicts of interest to disclose.

Funding: The authors have no funding to disclose.

Ethical Approval: All patient data were collected under internal review board–approved protocol.

Previous Presentation: This study was presented at the annual meeting of the American Society of Radiation Oncology held virtually; October 25–28, 2020; from Miami Beach, Florida.

References

1. Dulguerov P, Jacobsen MS, Allal AS, Lehmann W, Calcaterra T. Nasal and paranasal sinus carcinoma: are we making progress? a series of 220 patients and a systematic review. Cancer. 2001;92:3012–29.

2. Turner JH, Reh DD. Incidence and survival in patients with sinonasal cancer: a historical analysis of population-based data. Head Neck. 2012;34:877–85.

3. Dagan R, Amdur RJ, Dziegielewski PT. Tumors of the nasal cavity. In: Brockstein BE, Posner MR, Brizel DM, Fried MP, and Shah S, eds. UpToDate. Published 2020; Updated November 9, 2020.

4. Dagan R, Bryant C, Li Z, Yeung D, Justice J, Dziegielewski P, Werning J, Fernandes R, Pirgousis P, Lanza DC, Morris CG, Mendenhall WM. Outcomes of sinonasal cancer treated with proton therapy. Int J Radiat Oncol Biol Phys. 2016;95:377–85.

5. Hoppe BS, Stegman LD, Zelefsky MJ, Rosenzweig KE, Wolden SL, Patel SG, Shah JP, Kraus DH, Lee NY. Treatment of nasal cavity and paranasal sinus cancer with modern radiotherapy techniques in the postoperative setting—the MSKCC experience. Int J Radiat Oncol Biol Phys. 2007;67:691–702.

6. Chen AM, Daly ME, Bucci MK, Xia P, Akazawa C, Quivey JM, Weinberg V, Garcia J, Lee NY, Kaplan MJ, El-Sayed I, Eisele DW, Fu KK, Phillips TL. Carcinomas of the paranasal sinuses and nasal cavity treated with radiotherapy at a single institution over five decades: are we making improvement? Int J Radiat Oncol Biol Phys. 2007;69:141–7.

7. Dirix P, Nuyts S, Geussens Y, Jorissen M, Vander Poorten V, Fossion E, Hermans R, Van den Bogaert W. Malignancies of the nasal cavity and paranasal sinuses: long-term outcome with conventional or three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys. 2007;69:1042–50.

8. Hoppe BS, Nelson CJ, Gomez DR, Stegman LD, Wu AJ, Wolden SL, Pfister DG, Zelofsky MJ, Shah JP, Kraus DH, Lee NY. Unresectable carcinoma of the paranasal sinuses: outcomes and toxicities. Int J Radiat Oncol Biol Phys. 2008;72:763–9.

9. Mendenhall WM, Amdur RJ, Morris CG, Kirwan J, Malyapa RS, Vaysberg M, Werning JW, Mendenhall NP. Carcinoma of the nasal cavity and paranasal sinuses. Laryngoscope. 2009;119:899–906.

10. Lomax AJ, Goitein M, Adams J. Intensity modulation in radiotherapy: photons versus protons in the paranasal sinus. Radiother Oncol. 2003;66:11–8.

11. Mock U, Georg D, Bogner J, Auberger T, Potter R. Treatment planning comparison of conventional, 3D conformal, and intensity-modulated photon (IMRT) and proton therapy for paranasal sinus carcinoma. Int J Radiat Oncol Biol Phys. 2004;58:147–54.

12. Fan M, Kang JJ, Lee A, Fan D, Wang H, Kitpanit S, Fox P, Sine K, Mah D, McBride SM, Tsai CJ, Riaz N, Dunn LA, Sherman EJ, Michel L, Singh B, Ganly I, Wong RJ, Boyle JO, Cohen MA, Lee NY. Outcomes and toxicities of definitive radiotherapy and reirradiation using 3-dimensional conformal or intensity-modulated (pencil beam) proton therapy for patients with nasal cavity and paranasal sinus malignancies. Cancer. 2020;126:1905–16.

13. Russo AL, Adams JA, Weyman EA, Busse PM, Goldberg SI, Varvares M, Deschler DD, Lin DT, Delaney TF, Chan AW. Long-term outcomes after proton beam therapy for sinonasal squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2016;95:368–76.

14. Yu NY, Gamez ME, Hartsell WF, Tsai HK, Laramore GE, Larson GL, Simone CB II, Rossi C, Katz SR, Buras MR, Golafshar MA, Vargas CE, Patel SH. A multi-institutional experience of proton beam therapy for sinonasal tumors. Adv Radiat Oncol. 2019;4:689–98.
15. Patel SH, Wang Z, Wong WW, Murad MH, Buckey CR, Mohammed K, Alahdab F, Altayar O, Nabhan M, Schild SE, Foote RL. Charged particle therapy versus photon therapy for paranasal sinus and nasal cavity malignant diseases: a systematic review and meta-analysis. *Lancet Oncol*. 2014;15:1027–38.

16. Moyers MF, Miller DW, Bush DA, Slater JD. Methodologies and tools for proton beam design for lung tumors. *Int J Radiat Oncol Biol Phys*. 2001;49:1429–38.

17. Paganetti H. Relative biological effectiveness (RBE) values for proton beam therapy. Variations as a function of biological endpoint, dose, and linear energy transfer. *Phys Med Biol*. 2014;59:R419–72.

18. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines) head and neck cancers version 2.2020. https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf. Accessed June 9, 2020.

19. Sugiyama S, Katsui K, Tominaga Y, Waki T, Katayama N, Matsuzaki H, Kariya S, Kuroda M, Nishizaki K, Kanazawa S. Dose distribution of intensity-modulated proton therapy with and without a multi-leaf collimator for the treatment of maxillary sinus cancer: a comparative effectiveness study. *Radiat Oncol*. 2019;14:209.

20. Mayo C, Martel MK, Marks LB, Flickinger J, Nam J, Kirkpatrick J. Radiation dose-volume effects of optic nerves and chiasm. *Int J Radiat Oncol Biol Phys*. 2010;76(3 suppl):S28–35.

21. Bhandare N, Monroe AT, Morris CG, Bhatti MT, Mendenhall WM. Does altered fractionation influence the risk of radiation-induced optic neuropathy? *Int J Radiat Oncol Biol Phys*. 2005;62:1070–7.

22. Monroe AT, Bhandare N, Morris CG, Mendenhall WM. Preventing radiation retinopathy with hyperfractionation. *Int J Radiat Oncol Biol Phys*. 2005;61:856–64.

23. Jin MC, Harris JP, Sabolch AN, Gensheimer M, Le QT, Beadle BM, Pollom EL. Proton radiotherapy and treatment delay in head and neck squamous cell carcinoma [published online ahead of print December 14, 2019]. *Laryngoscope* 2020;130:E598–605.

24. Jiang W, Mohamed ASR, Fuller CD, Kim BYS, Tang C, Gunn GB, Hanna EY, Frank SJ, Su SY, Diaz E, Kupferman ME, Beadle BM, Morrison WH, Skinner H, Lai SY, El-Naggar AK, DeMonte F, Rosenthal DI, Garden AS, Phan J. The role of elective nodal irradiation for esthesioneuroblastoma patients with clinically negative neck. *Pract Radiat Oncol*. 2016;6:241–7.

25. Newlin HE, Amdur RJ, Riggs CE, Morris CG, Kinwan JM, Mendenhall WM. Concomitant weekly cisplatin and altered fractionation radiotherapy in locally advanced head and neck cancer. *Cancer*. 2010;116:4533–40.

26. Amit M, Abdelmeguid AS, Watcherporn T, Takahashi H, Tam S, Bell D, Ferrarotto R, Glisson B, Kupferman ME, Roberts DB, Su SY, Raza SM, DeMonte F, Hanna EY. Induction chemotherapy response as a guide for treatment optimization in sinusonal undifferentiated carcinoma. *J Clin Oncol*. 2019;37:504–12.

27. Dagan R, Bryant CM, Mendenhall WM, Amdur RJ, Morris CG, Lanza DC, Dziegielewski PT, Justice JM, Lobo BC, Silver NL, Fernandes R, Bunnell A, Guthrie T, Gopalak PK, Rahman M, Tavanaiepour D. Isolated leptomeningeal progression from sinonasal carcinomas: Implications for staging workup and treatment. *Head Neck*. 2019;41:2647–54.

28. Bishop JA, Andreassen S, Hang JF, Bullock MJ, Chen TY, Franchi A, Garcia JJ, Gnepp DR, Gomez-Fernandez CR, Ihrler S, Kuo YJ, Lewis JS Jr, Magliocca KR, Pambuccian S, Sandison A, Uro-Coste E, Stelow E, Kiss K, Westra WH. HPV-related multiphenotypic sinonasal carcinoma: an expanded series of 49 cases of the tumor formerly known as HPV-related carcinoma with adenoid cystic carcinoma-like features. *Am J Surg Pathol*. 2017;41:1690–701.

29. Bishop JA, Antonescu CR, Westra WH. SMARCB1 (INI-1)-deficient carcinomas of the sinonasal tract. *Am J Surg Pathol*. 2014;38:1282–9.

30. Bishop JA, Westra WH. NUT midline carcinomas of the sinonasal tract. *Am J Surg Pathol*. 2012;36:1216–21.